LEMAITRE VASCULAR, INC. (LMAT) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 191.31M USD | Gross Profit |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 71.13M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $191.31M | (m) | $71.13M | (m) |
| 2026-03-31 | $185.51M | (m) | $70.77M | (m) |
| 2025-12-31 | $178.54M | $249.60M | $71.06M | 71.53% |
| 2025-09-30 | $170.94M | (m) | $69.93M | (m) |
| 2025-06-30 | $162.16M | (m) | $72.48M | (m) |
| 2025-03-31 | $155.66M | (m) | $70.60M | (m) |
| 2024-12-31 | $150.90M | $219.86M | $68.96M | 68.63% |
| 2024-09-30 | $145.58M | $213.03M | $67.45M | 68.34% |
| 2024-06-30 | $139.21M | $205.62M | $66.41M | 67.70% |
| 2024-03-31 | $132.83M | $199.89M | $67.06M | 66.45% |
| 2023-12-31 | $127.05M | $193.48M | $66.44M | 65.66% |
| 2023-09-30 | $119.84M | (m) | $65.72M | (m) |
| 2023-06-30 | $114.09M | $177.17M | $63.08M | 64.40% |
| 2023-03-31 | $109.82M | $169.16M | $59.35M | 64.92% |
| 2022-12-31 | $104.90M | $161.65M | $56.76M | 64.89% |
| 2022-09-30 | $104.80M | $160.20M | $55.40M | 65.42% |
| 2022-06-30 | $104.59M | $159.54M | $54.95M | 65.56% |
| 2022-03-31 | $103.55M | $158.10M | $54.56M | 65.49% |
| 2021-12-31 | $101.38M | $154.42M | $53.04M | 65.65% |
| 2021-09-30 | $99.83M | $152.47M | $52.64M | 65.47% |
| 2021-06-30 | $97.67M | $150.52M | $52.85M | 64.89% |
| 2021-03-31 | $87.93M | $134.70M | $46.76M | 65.28% |
| 2020-12-31 | $84.62M | $129.37M | $44.75M | 65.41% |
| 2020-09-30 | $80.12M | $121.99M | $41.86M | 65.68% |
| 2020-06-30 | $77.59M | $114.67M | $37.09M | 67.66% |
| 2020-03-31 | $80.87M | $119.30M | $38.43M | 67.79% |
| 2019-12-31 | $79.85M | $117.23M | $37.38M | 68.12% |
| 2019-09-30 | $79.16M | $115.45M | $36.29M | 68.57% |
| 2019-06-30 | $76.25M | $110.52M | $34.26M | 69.00% |
| 2019-03-31 | $74.93M | $108.05M | $33.12M | 69.34% |
| 2018-12-31 | $73.94M | $105.57M | $31.63M | 70.04% |
| 2018-09-30 | $72.97M | $103.33M | (m) | 70.62% |
| 2018-06-30 | $73.29M | $103.99M | (m) | 70.48% |
| 2018-03-31 | $71.82M | $102.72M | (m) | 69.91% |
| 2017-12-31 | $70.70M | $100.87M | (m) | 70.09% |
| 2017-09-30 | $68.64M | $98.00M | (m) | 70.04% |
| 2017-06-30 | $68.08M | $96.40M | (m) | 70.63% |
| 2017-03-31 | $65.93M | $93.03M | (m) | 70.87% |
| 2016-12-31 | $62.94M | $89.15M | (m) | 70.59% |
| 2016-09-30 | $61.15M | $86.35M | (m) | 70.81% |
| 2016-06-30 | $57.64M | $82.16M | (m) | 70.16% |
| 2016-03-31 | $55.41M | $79.66M | (m) | 69.55% |
| 2015-12-31 | $54.17M | $78.35M | (m) | 69.13% |
| 2015-09-30 | $52.59M | $76.55M | (m) | 68.70% |
| 2015-06-30 | $51.08M | $75.03M | (m) | 68.08% |
| 2015-03-31 | $50.32M | $73.29M | (m) | 68.66% |
| 2014-12-31 | $48.43M | $71.10M | (m) | 68.12% |
| 2014-09-30 | $47.56M | $70.33M | (m) | 67.62% |
| 2014-06-30 | $46.27M | $68.13M | (m) | 67.92% |
| 2014-03-31 | $45.13M | $65.92M | (m) | 68.47% |
| 2013-12-31 | $45.12M | $64.55M | (m) | 69.89% |
| 2013-09-30 | $43.60M | $61.43M | (m) | 70.97% |
| 2013-06-30 | $42.90M | $59.78M | (m) | 71.76% |
| 2013-03-31 | $42.20M | $58.19M | (m) | 72.53% |
| 2012-12-31 | $40.87M | $56.73M | (m) | 72.03% |
| 2012-09-30 | $39.95M | $55.34M | (m) | 72.19% |
| 2012-06-30 | $40.12M | $56.26M | (m) | 71.31% |
| 2012-03-31 | $39.95M | $57.02M | (m) | 70.06% |
| 2011-12-31 | $40.23M | $57.69M | (m) | 69.74% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $41.72M | $56.06M | (m) | 74.42% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $37.30M | $50.91M | (m) | 73.28% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |